Ebola Vaccine Induces T Cell Cross-Reactivity Against Bundibugyo Virus in Humans

Licensed Ebola Vaccine Ervebo Triggered T Cells Against Bundibugyo in 13 of 20 Recipients, but Protection Remains Unproven

A small study found that Ervebo sparked Bundibugyo-reactive T cells in 13 of 20 adults. Here is what it means for the Congo trial and U.S. travelers.

Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus in humans

The current Bundibugyo Ebola virus (BDBV) outbreak in the Democratic Republic of the Congo is the second largest Ebola outbreak worldwide, with over 6,000 confirmed cases and a 48% fatality rate. There is currently no approved BDBV vaccine.

Licensed Ebola vaccine sparks immune cells that recognize a second deadly

A study led by the German Center for Infection Research shows that a single dose of the licensed Ebola virus vaccine Ervebo induces T cells in humans that cross-react with Bundibugyo virus and, to a lesser extent, Sudan virus.